Structured evidence table for Vitamin C Immune Support Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin C Immune Support Randomized Trial | Results We found no significant difference in GVHD occurrence and levels of retinoids between the intervention and control groups at either of the two time points. | 2 | Iversen PO (2026) | Plasma Levels of Retinoids and Carotenoids in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Given Extracorporeal Photopheresis to Prevent Graft-Versus-Host Disease-Analyses From a Randomized Trial. |
| Vitamin C Immune Support Randomized Trial | Conclusion Whether routine vitamin A supplementation is warranted for GVHD prevention, needs further study. | 2 | Iversen PO (2026) | Plasma Levels of Retinoids and Carotenoids in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Given Extracorporeal Photopheresis to Prevent Graft-Versus-Host Disease-Analyses From a Randomized Trial. |
| Vitamin C Immune Support Randomized Trial | Introduction Whether retinoids and carotenoids impact on graft-versus-host disease (GVHD) following allogeneic stem cell transplantation (ASCT) is unknown. | 2 | Iversen PO (2026) | Plasma Levels of Retinoids and Carotenoids in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Given Extracorporeal Photopheresis to Prevent Graft-Versus-Host Disease-Analyses From a Randomized Trial. |
| Vitamin C Immune Support Randomized Trial | Methods We conducted a 1:1 randomized controlled trial with extracorporeal photopheresis for GVHD-prophylaxis as the intervention. | 2 | Iversen PO (2026) | Plasma Levels of Retinoids and Carotenoids in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Given Extracorporeal Photopheresis to Prevent Graft-Versus-Host Disease-Analyses From a Randomized Trial. |
| Vitamin C Immune Support Randomized Trial | Resistance often develops through genetic changes in fungi, such as mutations in drug targets or increased drug efflux. | 3 | Akimbekov Nuraly S. (2026) | Vitamin D–AMP axis in host defense against fungal infections |
| Vitamin C Immune Support Randomized Trial | This growing problem poses a serious challenge to public health, limiting treatment options and increasing the risk of adverse outcomes for patients, particularly those with invasive candidiasis and mold disease (). | 3 | Akimbekov Nuraly S. (2026) | Vitamin D–AMP axis in host defense against fungal infections |
| Vitamin C Immune Support Randomized Trial | Growing evidence suggests that vitamin D increases innate immunity by regulating the production of AMPs (). | 3 | Akimbekov Nuraly S. (2026) | Vitamin D–AMP axis in host defense against fungal infections |
| Vitamin C Immune Support Randomized Trial | This trend is concerning, as it is coupled with the emergence of drug-resistant fungal strains and limited treatment options, leading to a substantial global health burden (). | 3 | Akimbekov Nuraly S. (2026) | Vitamin D–AMP axis in host defense against fungal infections |
Source documents